|Bid||4,200.00 x 0|
|Ask||4,210.00 x 0|
|Day's range||4,195.00 - 4,285.00|
|52-week range||3,500.00 - 5,060.00|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||9.21|
|Earnings date||12 Aug 2022|
|Forward dividend & yield||130.00 (3.17%)|
|Ex-dividend date||29 Dec 2022|
|1y target est||5,177.00|
NEW YORK, May 10, 2022--As part of its ambition and commitment to unlock opportunities for growth and good across the entire healthcare ecosystem, dentsu health announced today two key senior appointments. To elevate dentsu health’s research and audience capabilities, Data Scientist Olympia Mantsios has been appointed Global VP Data & Analytics. And, to accelerate the transformation of dentsu health’s product offerings, Lynda Gordon will join as SVP, Product Development.
TORONTO, April 28, 2022--Dentsu Canada announced today the merger of Antibody, Canada’s premier full-service communications agency, with dentsu health. The merger follows on the heels of rapid growth for the global healthcare solution.
NEW YORK, April 01, 2022--Dentsu Health today announced the appointment of healthcare marketing industry veteran Susan Johnson, as SVP, Integrated Client Director, and Stephen O’Dea, as VP, Global Health Media. Susan and Stephen’s appointments followed a series of high-profile recruitments at dentsu health since its launch last year.